Selling off IVOB

I got out at .20-.21, and took a small loss. I sold based on their quarterly report:

International sales will continue to be our only source of revenue for the coming year. We are aware of many significant international opportunities and we expect international revenues to continue to grow. International sales are, however, difficult to forecast.

Net sales and revenue for the second quarter of 2009 increased 100% to $16,600 compared to no revenue for the same period in 2008. The increase was due to starting international shipments of small orders to our newly signed distributors as well as direct shipments to physicians who want to use the INVOcell. The Company expects revenues to grow slowly as we move into Spain, Italy and Peru, adding to our current customer base in Turkey, the Mid-East and Colombia. Liquidity and Capital Resources We are currently seeking up to $5 million in capital through a private placement of our common stock. The exact amount of funds raised, if any, will determine how aggressively we can grow and what additional projects we will be able to undertake. As of June 30, 2009, we had $100 in cash and no cash equivalents. As of June 30, 2009, we require approximately $175,000 per month to fund our operations. Net cash used by operating activities was $349,000 for the six months ended June 30, 2009, compared to net cash used by operating activities of $159,000 for the six months ended June 30, 2008. The increase in net cash used was due to the significant costs of staffing, compliance, introducing our products into new markets and the establishment of an Advisory Board and consulting in preparation of our FDA 510k submission. In addition, all of the current employees have assisted INVO Bioscience in its funding requirements by deferring their salaries for the last four months ending June 30, 2009. The Company's existing cash resources, cash flow from operations and short-term borrowings on the existing credit line or from management will not provide adequate resources for supporting operations during fiscal 2009. The Company is actively seeking the funding it needs to continue to execute its business plan. It is doing so in two steps, first with a $500,000 10% convertible note bridge offering while it lines up a $5 million dollar Private Investment in a Public Entity (PIPE) Common Stock offering. On July 15, 2009, the Company consummated the initial closing of the bridge offering in the total principal amount of $100,000 to one accredited investor. However, if we do not raise additional capital in the near future we will have to further curtail our spending and downsize our operations.